Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in the VITAL study

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 260-264

  Brasky, Theodore M ^a,b   Baik, Christina S ^a   Slatore, Christopher G ^c,d   Potter, John D ^a   White, Emily ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aspirin; Ibuprofen; NSAID; Small cell lung cancer

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; SMOKING;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SMALL CELL LUNG CARCINOMA; WASHINGTON;

EID: 84863779153     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.015     Document Type: Article

References (26)

1. Lee J.M., Yanagawa J., Peebles K.A., Sharma S., Mao J.T., Dubinett S.M. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008, 66:208-217.
2. Khuder S.A., Herial N.A., Mutgi A.B., Federman D.J. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005, 127:748-754.
3. Oh S.W., Myung S.K., Park J.Y., Lee C.M., Kwon H.T. Aspirin use and risk for lung cancer: a meta-analysis. Ann Oncol 2011, 22:2456-2465.
4. Xu J., Yin Z., Gao W., Liu L., Wang R., Huang P., et al. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin Lung Cancer 2011.
5. Cook N.R., Lee I.M., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., et al. Low-dose aspirin in the primary prevention of cancer: the women's health study: a randomized controlled trial. JAMA 2005, 294:47-55.
6. Rothwell P.M., Fowkes F.G.R., Belch J.F.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. The Lancet 2011, 377. 31-41+.
7. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58:3761-3764.
8. Hayes J.H., Anderson K.E., Folsom A.R. Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2006, 15:2226-2231.
9. Slatore C.G., Au D.H., Littman A.J., Satia J.A., White E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 2009, 18:1203-1207.
10. White E., Patterson R.E., Kristal A.R., Thornquist M., King I., Shattuck A.L., et al. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 2004, 159:83-93.
11. Grosser T., Smyth E., FitzGerald G. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. Goodman and Gilman's the pharmacological basis of therapeutics 2011, 960-1004. McGraw Hill, New York. 12th ed. L. Brunton (Ed.).
12. Field R.W., Smith B.J., Platz C.E., Robinson R.A., Neuberger J.S., Brus C.P., et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004, 96:1105-1107.
13. Slatore C.G., Littman A.J., Au D.H., Satia J.A., White E. Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am J Respir Crit Care Med 2008, 177:524-530.
14. Navarro S.L., Saracino M.R., Makar K.W., Thomas S.S., Li L., Zheng Y., et al. Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases. J Nutrigenet Nutrigenomics 2011, 4:110-118.
15. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009, 76:215-228.
16. Freedman N.D., Leitzmann M.F., Hollenbeck A.R., Schatzkin A., Abnet C.C. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 2008, 9:649-656.
17. Brasky T.M., Potter J.D., Kristal A.R., Patterson R.E., Peters U., Asgari M.M., et al. Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control 2012.
18. Kelly J.P., Coogan P., Strom B.L., Rosenberg L. Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 2008, 17:322-327.
19. McCormack V.A., Hung R.J., Brenner D.R., Bickeboller H., Rosenberger A., Muscat J.E., et al. Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control 2011, 22:1709-1720.
20. Moysich K.B., Menezes R.J., Ronsani A., Swede H., Reid M.E., Cummings K.M., et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002, 2:31.
21. Muscat J.E., Chen S.Q., Richie J.P., Altorki N.K., Citron M., Olson S., et al. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer 2003, 97:1732-1736.
22. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Supplement to: effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377. [Webappendix].
23. Franconi F., Brunelleschi S., Steardo L., Cuomo V. Gender differences in drug responses. Pharmacol Res 2007, 55:81-95.
24. Mollerup S., Berge G., Baera R., Skaug V., Hewer A., Phillips D.H., et al. Sex differences in risk of lung cancer: expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer 2006, 119:741-744.
25. Gallagher C.J., Balliet R.M., Sun D., Chen G., Lazarus P. Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos 2010, 38:2204-2209.
26. Gallagher C.J., Muscat J.E., Hicks A.N., Zheng Y., Dyer A.M., Chase G.A., et al. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:823-828.